Mobility management in HetNets: a learning-based perspective

Heterogeneous networks (HetNets) are expected to be a key feature of long-term evolution (LTE)-advanced networks and beyond and are essential for providing ubiquitous broadband user throughput. However, due to different coverage ranges of base stations (BSs) in HetNets, the handover performance of a user equipment (UE) may be significantly degraded, especially in scenarios where high-velocity UE traverse through small cells. In this article, we propose a context-aware mobility management (MM) procedure for small cell networks, which uses reinforcement learning techniques and inter-cell coordination for improving the handover and throughput performance of UE. In particular, the BSs jointly learn their long-term traffic loads and optimal cell range expansion and schedule their UE based on their velocities and historical data rates that are exchanged among the tiers. The proposed approach is shown not only to outperform the classical MM in terms of throughput but also to enable better fairness. Using the proposed learning-based MM approaches, the UE throughput is shown to improve by 80% on the average, while the handover failure probability is shown to reduce up to a factor of three

A p-adic look at the Diophantine equation x^{2}+11^{2k}=y^{n}

We find all solutions of Diophantine equation x^{2}+11^{2k} = y^{n} where x>=1, y>=1, n>=3 and k is natural number. We give p-adic interpretation of this equation.Comment: 4 page

Safety and clinical efficacy of golimumab in the treatment of arthritides

Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. This review covers the published clinical trial data on the use of golimumab for the approved indications mentioned above with respect to efficacy and safety. The various ongoing trials for golimumab have yielded promising results in terms of efficacy and safety in methotrexate-naive and -resistant patients with rheumatoid arthritis, as well as in patients who were previously treated with other anti-TNF agents. In addition, the efficacy of golimumab in psoriatic arthritis and ankylosing spondylitis has also been demonstrated. The real safety information will be available only once the drug has been used in many more patients, who frequently have comorbid conditions

SHORT-TERM EFFECTS OF 3 DAYS INTENSIVE WHOLE BODY VIBRATION EXPOSURE ON MUSCULAR ACTIVATION STRATEGIES

The aim of this study was to investigate 3-days intensive whole body vibration (WBV) exposure on activation strategies of lower extremity muscles. For this purpose, six male athletes’ dominant leg muscles (Tibialis Anterior(TA), Gastrocnemious Medialis(GM), Vastus Medialis(VM), Rectus Femoris(RF), Vastus Lateralis(VL) and Biceps Femoris(BF)) were recruited voluntarily. Before the trails their baseline electromyography (EMG) values were taken for reference evaluation. After that, they were trained static semi-squat position with 120o knee flexion angle on vibration platform (vertical vibration; 4 mm(high), 30 Hz), during 3 days. The subjects were exposed to vibration 6 times for duration of 60 seconds with a 2 minutes rest between each treatment. Consequently, 3 days intensive WBV exposure caused a progressive increase in EMG activity (